Skip to main content

A metalloporphyrin antioxidant alters cytokine responses after irradiation in a prostate tumor model.

Publication ,  Journal Article
Makinde, AY; Rizvi, A; Crapo, JD; Pearlstein, RD; Slater, JM; Gridley, DS
Published in: Radiat Res
April 2010

The goal of this study was to evaluate cytokine secretion capacity in a mouse model of prostate cancer, both with and without metalloporphyrin antioxidant and radiation treatment. C57BL/6 mice with subcutaneous RM-9 tumors were treated daily for 12 days with MnTE-2-PyP(5+) [Mn (III) tetrakis (N-ethylpyridinium-2-yl) porphyrin], beginning 1 day after injection of RM-9 cells; a 10-Gy tumor-localized dose of (60)Co gamma rays was administered in a single fraction on day 7. Spleen, tumors and plasma were collected on day 12. T cells in the spleen were activated with anti-CD3 antibody and supernatants were collected. Twenty-two cytokines were quantified in spleen supernatants, five in tumor homogenates, and three in plasma using multiplex bead array technology and ELISA. The presence of a tumor had significant effects on many of the cytokines quantified (P < 0.05). Tumor-induced depression was evident for eight spleen cytokines (TNF-alpha, G-CSF, GM-CSF, IFN-gamma, IL10, IP-10, MIP-1alpha and mKC), whereas only three were enhanced (IL1beta, IL6 and MCP-1). Radiotherapy resulted in enhanced splenocyte capacity to produce IL4 and IL13 and increased IL4, MCP-1 and VEGF in tumors (P < 0.05). Addition of MnTE-2-PyP(5+) to radiation decreased the concentrations of IL4, IL13 and TGF-beta1 in spleen supernatants and IL4 and VEGF in tumors (P < 0.05 compared to radiation alone). Some differences were also noted in plasma cytokines. Overall, the findings suggest that administration of MnTE-2-PyP(5+) together with radiotherapy may enhance anti-tumor immune responsiveness and decrease the risk for radiation-induced normal tissue toxicities.

Duke Scholars

Published In

Radiat Res

DOI

EISSN

1938-5404

Publication Date

April 2010

Volume

173

Issue

4

Start / End Page

441 / 452

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Radiotherapy, Conformal
  • Radiation Dosage
  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Mice, Inbred C57BL
  • Mice
  • Metalloporphyrins
  • Male
  • Dose-Response Relationship, Radiation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Makinde, A. Y., Rizvi, A., Crapo, J. D., Pearlstein, R. D., Slater, J. M., & Gridley, D. S. (2010). A metalloporphyrin antioxidant alters cytokine responses after irradiation in a prostate tumor model. Radiat Res, 173(4), 441–452. https://doi.org/10.1667/RR1765.1
Makinde, Adeola Y., Asma Rizvi, James D. Crapo, Robert D. Pearlstein, James M. Slater, and Daila S. Gridley. “A metalloporphyrin antioxidant alters cytokine responses after irradiation in a prostate tumor model.Radiat Res 173, no. 4 (April 2010): 441–52. https://doi.org/10.1667/RR1765.1.
Makinde AY, Rizvi A, Crapo JD, Pearlstein RD, Slater JM, Gridley DS. A metalloporphyrin antioxidant alters cytokine responses after irradiation in a prostate tumor model. Radiat Res. 2010 Apr;173(4):441–52.
Makinde, Adeola Y., et al. “A metalloporphyrin antioxidant alters cytokine responses after irradiation in a prostate tumor model.Radiat Res, vol. 173, no. 4, Apr. 2010, pp. 441–52. Pubmed, doi:10.1667/RR1765.1.
Makinde AY, Rizvi A, Crapo JD, Pearlstein RD, Slater JM, Gridley DS. A metalloporphyrin antioxidant alters cytokine responses after irradiation in a prostate tumor model. Radiat Res. 2010 Apr;173(4):441–452.

Published In

Radiat Res

DOI

EISSN

1938-5404

Publication Date

April 2010

Volume

173

Issue

4

Start / End Page

441 / 452

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Radiotherapy, Conformal
  • Radiation Dosage
  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Mice, Inbred C57BL
  • Mice
  • Metalloporphyrins
  • Male
  • Dose-Response Relationship, Radiation